Abstract
Background: Seasonal affective disorder (SAD) is common and debilitating. The standard of care includes light therapy provided by a light box; however, this treatment is restrictive and only moderately effective. Advances in LED technology enable lighting solutions that emit vastly more light than traditional light boxes. Here, we assess the feasibility of BROAD (Bright, whole-ROom, All-Day) light therapy and get a first estimate for its potential effectiveness. Methods: Patients were randomly assigned to a treatment for four weeks; either a very brightly illuminated room in their home for at least six hours per day (BROAD light therapy) or 30 minutes in front of a standard 10,000 lux SAD light box. Feasibility was assessed by monitoring recruitment, adherence, and side effects. SAD symptoms were measured at baseline and after two and four weeks, with the Hamilton Depression Rating Scale-Seasonal Affective Disorders 29-items, self-report version. Results: All 62 patients who started treatment were available at four-week follow-up and no significant adverse effects were reported. SAD symptoms of both groups improved similarly and considerably, in line with previous results. Exploratory analyses indicate that a higher illuminance (lux) is associated with a larger symptom improvement in the BROAD light therapy group. Conclusions: BROAD light therapy is feasible and seems similarly effective as the standard of care while not confining the participants to 30 minutes in front of a light box. In follow-up trials, BROAD light therapy could be modified for increased illuminance, which would likely improve its effectiveness.
Introduction
Seasonal Affective Disorder (SAD) affects up to 10% of the population in northern latitudes. For decades, the "standard of care" has remained largely unchanged: sitting 20cm away from a 10,000 lux light box for 30 minutes every morning. This protocol has two major flaws. First, it is restrictive; users are essentially anchored to a desk, which hurts long-term adherence. Second, it may provide an insufficient "dose." Natural summer light—the environment in which SAD symptoms typically remit—is characterized by homogeneous illumination across the entire visual field and durations lasting many hours.
This study evaluates a novel alternative: "BROAD" (Bright, whole-ROom, All-Day) light therapy. By leveraging modern, inexpensive LED technology, researchers hypothesized they could recreate a "summer-like" indoor environment that is both more convenient and more therapeutically potent.
Methods
The researchers conducted a randomized, partially blind, parallel-group proof-of-concept trial with 62 participants diagnosed with SAD.
Participants were randomly assigned to one of two groups:
- The BROAD Intervention: Participants installed one or two 10m–20m socket cords containing 40–70 bright LED bulbs (totaling 72,000 to 102,000 lumens) in a room where they spent at least six hours a day.
- The Active Control: Participants used a standard, commercially available 10,000 lux SAD light box for 30 minutes per day.
The study lasted four weeks. Symptoms were tracked using the SIGH-SAD-SR (a 29-item self-report version of the Hamilton Depression Rating Scale). Primary data, including symptom scores and adherence logs, is openly available via the Open Science Framework (OSF).
Results and Key Insights
The trial demonstrated that BROAD light therapy is highly feasible. Despite the DIY nature of hanging 70 bulbs in a living room, the study had a 100% retention rate for those who started treatment, and no significant adverse effects were reported.
Efficacy and the Lux-Response Relationship
Both groups showed considerable improvement. The BROAD group improved by an average of 11.58 points, while the control group improved by 13.24 points. While the difference between groups was not statistically significant in this small sample, exploratory analysis within the BROAD group revealed a critical "lux-response" relationship.
Because room sizes and setups varied, participants received different levels of illuminance (from 500 to 6,800 lux at eye level). The researchers found that every doubling of illuminance predicted an additional 4-point improvement on the SIGH-SAD scale. Participants in the BROAD group who received above-median illuminance (>1,400 lux) experienced a mean improvement of 16.7 points, notably higher than the active control average.
Adherence and Remission
Participants in the BROAD group successfully integrated the therapy into their lives, averaging 6.75 hours of exposure on treatment days. After four weeks, 22% of the BROAD group and 20% of the control group were in full clinical remission.
Discussion and Conclusion
The study suggests that the quality of light—specifically filling the entire visual field rather than a small "spot" from a box—might be a critical factor in therapeutic efficacy. While the BROAD setup provided lower instantaneous light at the eye (avg. ~1,500 lux) compared to a light box (10,000 lux), the total "light dose" over 6+ hours was much higher.
Limitations include a small sample size and potential placebo effects, as light boxes are marketed as medical devices while the BROAD setup used industrial components. However, the findings establish that BROAD light therapy is a feasible and safe alternative that does not tether patients to a light box. Future trials should focus on increasing standardized illuminance to further improve effectiveness.
Summary updated